Investing.com - Financial Markets Worldwide
⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

BRIEF-Resverlogix receives approval pathway from the FDA as to the inclusion of USA patients in the phase 3 betonmace trial

Published 2017-07-25, 09:22 a/m
© Reuters. BRIEF-Resverlogix receives approval pathway from the FDA as to the inclusion of USA patients in the phase 3 betonmace trial
RVX
-

July 25 (Reuters) - Resverlogix Corp RVX.TO :

* Resverlogix receives approval pathway from the FDA as to the inclusion of usa patients in the phase 3 betonmace trial

* Resverlogix Corp - receipt of a positive type c written response from division of metabolism and endocrinology products of U.S. FDA

* Resverlogix Corp- agreed to make adjustments to existing betonmace study protocol and to update investigator's brochure and informed consent documents

* Resverlogix-FDA approval to proceed with phase 3 betonmace trial in USA well timed, should not have major impact on total duration of betonmace trial

Latest comments

Loading next article…
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.